Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 7/20 | 0.51 |
| ▸ | CA1 | P00915 | 6/20 | 0.51 |
| ▸ | CA9 | Q16790 | 6/20 | 0.51 |
| ▸ | CA12 | O43570 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2338056 | 0.80 | LDHA (0.56) | LDHACA2SMN1; SMN2KMT2ANPSR1 | |
| SCHEMBL2335571 | 0.78 | LDHA (0.54) | LDHACA2CA1CA9CA12 | |
| SCHEMBL2342303 | 0.78 | PRSS1 (0.45) | CA2CA1CA9SMN1; SMN2CA5A | |
| SCHEMBL3161608 | 0.77 | KMT2A (0.45) | ALDH1A1KMT2AGAAPOLB | |
| SCHEMBL2338650 | 0.76 | HSD17B10 (0.44) | MAPTALDH1A1KMT2APOLB | |
| SCHEMBL490731 | 0.74 | LDHA (1.00) | LDHACA2CA1CA9CA12 | |
| SCHEMBL23761311 | 0.74 | LDHA (0.73) | LDHAALDH1A1 | |
| SCHEMBL28274764 | 0.73 | LDHA (0.48) | LDHACA2CA1CA9CA12 | |
| SCHEMBL11911907 | 0.73 | LDHA (0.78) | LDHACA2CA1CA9CA12 | |
| SCHEMBL7205819 | 0.73 | CA2 (0.59) | LDHACA2CA1CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735620-B2 | Processes for preparing (E)-styrylbenzylsulfone compounds and uses thereof for treating proliferative disorders | EPR PHARMACEUTICALS PVT. LTD (IN) | 2014-05-27 | — | — | US | disclosed |
| EP-1305015-B1 | SUBSTITUTED STYRYL BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2013-06-12 | — | — | EP | disclosed |
| EP-2359819-A1 | Substituted styryl benzylsulfones for treating proliferative disorders | Temple University - Of The Commonwealth System of Higher Education (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20100152491-A1 | PROCESSES FOR PREPARING (E)-STYRYLBENZYLSULFONE COMPOUNDS AND USES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | EPR PHARMACEUTICALS PVT.LTD | 2010-06-17 | — | — | US | disclosed |
| US-6642410-B2 | Useful as antiproliferative agents, including, for example, anticancer agents | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2003-11-04 | — | — | US | disclosed |
| EP-1305015-A4 | SUBSTITUTED STYRYL BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2003-05-21 | — | — | EP | disclosed |
| EP-1305015-A1 | SUBSTITUTED STYRYL BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | Temple University of the Commonwealth System of Higher Education (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20030036536-A1 | Useful as antiproliferative agents, including, for example, anticancer agents | REDDY E PREMKUMAR (US) | 2003-02-20 | — | — | US | disclosed |
| US-6486210-B2 | SUCH AS ENANTIOMORPHS OF 4-FLUOROSTYRYL-2,3,4,5,6-PENTAFLUOROBENZYLSULFONE; ANTIPROLIFERATIVE/ANTICANCER AGENTS | Temple University—Of the Commonwealth System of Higher Education | 2002-11-26 | — | — | US | disclosed |
| US-20020115643-A1 | Substituted styryl benzylsulfones for treating proliferative disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-08-22 | — | — | US | disclosed |
| WO-2001078712-A1 | SUBSTITUTED STYRYL BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152491-A1 | PROCESSES FOR PREPARING (E)-STYRYLBENZYLSULFONE COMPOUNDS AND USES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | PCNA, CDC25B, CCNB1 | LDHA 2469/4885CA2 3850/4885CA1 4149/4885 |
| US-20030036536-A1 | Useful as antiproliferative agents, including, for example, anticancer agents | MKI67, MCL1, CCNA1 | LDHA 2927/4885CA2 3943/4885CA1 4254/4885 |
| US-20020115643-A1 | Substituted styryl benzylsulfones for treating proliferative disorders | HCCS, CCNO, HRAS | LDHA 2202/4885CA2 1209/4885CA1 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.